RELEVIUM ANNOUNCES AGREEMENT WITH NEPTUNE WELLNESS FOR MAXSIMIL®
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the signing of a product development, supply and commercialization agreement with Neptune Wellness Solutions (TSX / NASDAQ : “NEPT”) for MaxSimil®, a patented fish oil monoglyceride omega 3 technology.
Highlights
- MaxSimil® is a technology that enhances the absorption of lipid and lipid-soluble ingredients in the production of nutraceuticals
- The agreement includes product development, supply and commercialization for Canada and USA
- Initial 2-year term
- Development of two (2) products in year one and an additional six (6) within year two
- The agreement includes Research and Development contribution by Relevium in the form of a 2.5% royalty on net sales payable to Neptune quarterly
Aurelio Useche, Relevium’s CEO “We are very pleased to partner with Neptune Wellness to develop new formulations combining MaxSimil® technology with plant derivatives and other nutraceutical ingredients, which will form part of current and future exclusive science-based brands” Mr. Useche continued: “The MaxSimil technology could prove to be a real differentiator for products marketed through our subsidiaries BGX Health and Biocannabix Health and their brands”
Francois-Karl Brouillette, Neptune’s VP, Science and Innovation stated:” Relevium’s business and product development strategies will be great accelerators to Neptune’s own MaxSimil® nutraceutical development program. Free of any unwanted excipients and mimicking our natural biological system, MaxSimil technology is an efficient nutraceutical-type delivery system that is perfectly compatible with today’s dietary supplement industry.” Mr. Brouillette added: “I strongly believe that this exciting new partnership will help us further unlock this patented technology’s full potential while extending its reach to a broader consumer base.”
About MaxSimil®
MaxSimil is a novel, patented delivery platform that enhances the absorption of lipid-based and lipid-soluble nutraceuticals. MaxSimil mimics the human digestive process to deliver absorption-ready, pre-digested lipid-based products such as plant and fish derived oils.
About Neptune Wellness Solutions
Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company formulates and provides turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions and formulations in high potential growth segments such as medical and wellness cannabinoid-based products. The Company’s head office is located in Laval, Quebec.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses and entrepreneurial brands in the growing health and wellness sector. The Company creates value by building brand equity, organic product offering and geographic expansion. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook, Follow us on Twitter
and Follow us on LinkedIn
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
